
Pfizer-BioNTech Vaccine Claimed 90% Effective
Phase 3 clinical trials with the mRNA vaccine candidate BNT162b2 being developed by US pharma giant Pfizer and German biotech partner BioNTech have shown it to be more than 90% effective in preventing Covid-19 in participants without evidence of prior SARS-CoV-2 infection, the companies announced in a preliminary look at efficacy.










































